Trulicity Cost in Kentucky 2026: Cash Price, Medicaid, and Cheaper Alternatives

What Does Trulicity Actually Cost in Kentucky Right Now?

The manufacturer list price for Trulicity in Kentucky is $931 per month in 2026, which equals roughly $11,172 per year paid entirely out of pocket. That number applies to the standard 4-pen monthly supply across all doses (0.75 mg, 1.5 mg, 3 mg, and 4.5 mg). Independent pharmacy data confirm that Kentucky retail prices track almost exactly to the Eli Lilly wholesale acquisition cost, with very little regional variation between Louisville, Lexington, Bowling Green, or rural counties.

The $931 figure is the price most cash-pay patients in Kentucky will encounter at CVS, Walgreens, Kroger Pharmacy, and independent pharmacies. GoodRx and similar discount cards bring the price down modestly, sometimes to $850, $900 per month, but that ceiling remains unaffordable for most uninsured Kentuckians. The median household income in Kentucky was $58 to 218 in 2023 according to U.S. Census data, meaning the cash price for Trulicity alone would consume roughly 19% of gross income for a median-income household.

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist administered as a once-weekly subcutaneous injection. The FDA approved dulaglutide (Trulicity) for glycemic control in adults with type 2 diabetes, and later for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease or multiple risk factors. [1] The REWIND trial (N=9,901) published in The Lancet in 2019 demonstrated that dulaglutide 1.5 mg weekly reduced the composite of major adverse cardiovascular events (MACE) by 12% compared with placebo (hazard ratio 0.88 to 95% CI 0.79, 0.99, P=0.026) over a median 5.4 years of follow-up. [2] That cardiovascular data is part of why physicians and telehealth providers across Kentucky prescribe dulaglutide even when cost is a barrier.

Does Kentucky Medicaid Cover Trulicity?

Kentucky Medicaid does not cover Trulicity (dulaglutide) for type 2 diabetes as of 2026. This is one of the most common questions from Kentucky patients, and the answer is a clear no for brand-name Trulicity on the Kentucky Medicaid preferred drug list.

Kentucky Medicaid (administered through managed care organizations including Aetna Better Health of Kentucky, Anthem Kentucky Medicaid, Humana CareSource, Molina Healthcare of Kentucky, and WellCare of Kentucky) restricts GLP-1 receptor agonist coverage heavily. For Medicaid members, prior authorization may be available for GLP-1 agents in specific clinical circumstances, such as co-existing cardiovascular disease or documented failure of multiple first-line agents, but brand-name Trulicity is not listed as a covered drug under standard Kentucky Medicaid formulary terms. Patients should call the member services number on their Medicaid card and explicitly request a formulary exception or prior authorization for dulaglutide, citing the REWIND cardiovascular outcome data if applicable. [2]

The Kentucky Department for Medicaid Services publishes quarterly preferred drug list updates. Providers can submit prior authorization requests through the Kentucky MMIS portal, and denials can be appealed within 10 days under Kentucky Administrative Regulation 907 KAR 1:563. A denial for medical necessity is not final until that appeal window closes.

For dually eligible patients (Medicare/Medicaid), Medicare Part D plans vary considerably. Some Part D plans do include dulaglutide on Tier 3 or Tier 4 formulary positions, which may reduce cost to $40, $100 per month with a savings card layered on top, depending on the plan year benefit design.

How the Eli Lilly Savings Card Works for Kentucky Patients

Commercially insured Kentucky patients may pay as little as $25 per month for Trulicity through the Lilly Insulin Value Program or the Trulicity Savings Card. The Lilly savings card is not a patient assistance program. It is a co-pay card for people who already have commercial insurance that covers Trulicity but have a high co-pay.

To use the savings card, a Kentucky patient must meet all of the following conditions: (1) have commercial insurance (employer-sponsored, ACA marketplace plan, or private plan) that covers Trulicity, (2) not be enrolled in any federal or state government insurance program including Medicare, Medicaid, TRICARE, or a federal employee health benefit plan, and (3) fill the prescription at a participating retail or mail-order pharmacy. The card caps patient out-of-pocket cost at $25 per 28-day supply for eligible patients. The maximum benefit through the Lilly savings card is $150 per fill for Trulicity. [3]

Patients who do not qualify for the savings card because they are uninsured may apply for the Lilly Cares Foundation Patient Assistance Program, which provides free Trulicity to qualifying low-income patients. The income eligibility threshold for the Lilly Cares program is set at 400% of the federal poverty level, which in 2026 equals approximately $60,240 for a single adult. Enrollment requires a physician signature, proof of income, and proof of no insurance coverage. Processing takes roughly 2 to 4 weeks for initial approval.

The HealthRX clinical team uses a four-step access framework for Kentucky patients who are told Trulicity is unaffordable at their pharmacy: (1) confirm commercial insurance status and apply for the Lilly savings card if eligible, (2) if uninsured and income is below 400% FPL, apply for Lilly Cares, (3) if ineligible for both, request a prior authorization through Kentucky Medicaid citing cardiovascular outcome data, and (4) if all three fail, discuss 503A compounded dulaglutide with a licensed Kentucky prescriber. Patients who skip directly to step four without attempting steps one through three often leave significant savings on the table.

Is Compounded Dulaglutide Legal in Kentucky?

Yes. Licensed 503A compounding pharmacies operating in Kentucky may legally prepare dulaglutide under certain conditions. The 503A designation refers to traditional compounding pharmacies that prepare medications for individual patient prescriptions under the federal Drug Quality and Security Act of 2013, as implemented through FDA guidance and Kentucky Board of Pharmacy regulations. [4]

The legal pathway for compounded dulaglutide in Kentucky depends on a valid, patient-specific prescription from a licensed prescriber. Kentucky pharmacy law (KRS Chapter 315) permits compounding of commercially available drug products if there is a documented clinical rationale, such as a specific dose not commercially available or a documented allergy to an inactive ingredient in the brand product. Pharmacies operating under 503A rules do not require FDA approval to compound specific formulations, but they cannot manufacture in bulk without a valid prescription for each patient. [4]

As of 2026, dulaglutide is not on the FDA's drug shortage list in the same way that semaglutide was during 2022 to 2024. The FDA's enforcement posture toward compounded GLP-1 products evolved significantly following the removal of semaglutide from the shortage list in early 2025. Prescribers and patients in Kentucky should verify the current FDA guidance status before initiating compounded dulaglutide, because FDA enforcement discretion policies can change. The FDA's current guidance on compounded drug products is available at fda.gov. [4]

Cost of compounded dulaglutide at a licensed Kentucky 503A pharmacy varies by dose and pharmacy, but patients have reported prices ranging from $150 to $350 per month, compared to the $931 brand list price. However, compounded products are not bioequivalent-tested in the same way as FDA-approved generics, and HealthRX recommends patients have this discussion directly with their prescriber.

Kentucky Board of Pharmacy contact information: 125 Holmes Street, Suite 300, Frankfort, KY 40601. Phone: 502-564-7910. Patients can verify a pharmacy's 503A status through the board's online licensee search.

Telehealth Prescribing of Trulicity in Kentucky

Kentucky permits telehealth prescribing of Trulicity. A prescriber licensed in Kentucky may write a prescription for dulaglutide following a synchronous audiovisual telehealth visit that meets the standard of care for establishing a prescriber-patient relationship.

Kentucky House Bill 144 (2020) and subsequent Kentucky telehealth regulations (KRS 211.332) codified telehealth prescribing rights that expanded during the COVID-19 public health emergency. As of 2026, those expanded rights remain in place for most non-controlled substances. Dulaglutide is not a controlled substance, so the prescribing requirements are the same via telehealth as in person: the prescriber must take a clinical history, review current medications, and determine that dulaglutide is appropriate for the patient's diagnosis. [5]

Telehealth platforms operating in Kentucky, including HealthRX, must be staffed by prescribers holding an active Kentucky medical license or a valid Kentucky telehealth registration if licensed in another state. The Kentucky Board of Medical Licensure offers a telehealth registration pathway for out-of-state providers through the Interstate Medical Licensure Compact, of which Kentucky is a member state.

Patients using telehealth to obtain a Trulicity prescription in Kentucky should expect a clinical intake that covers: current HbA1c and fasting glucose, any prior GLP-1 therapy, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), renal function if relevant, and current diabetes medications. The FDA label for Trulicity carries a boxed warning about thyroid C-cell tumor risk, which every prescriber must address regardless of visit modality. [1]

Which Commercial Insurance Plans Cover Trulicity in Kentucky?

Most large commercial insurance plans sold in Kentucky cover Trulicity, but the tier placement and prior authorization requirements vary. Employer-sponsored plans administered by Anthem Blue Cross Blue Shield of Kentucky, Humana, Aetna, Cigna, and UnitedHealthcare typically place dulaglutide on Tier 3 (preferred specialty) or Tier 4 (non-preferred specialty), with co-pays ranging from $40 to $200 per month depending on plan design.

The Kentucky Health Benefit Exchange (kynect) offers ACA marketplace plans from Anthem and Ambetter. Formulary details change each plan year. For the 2026 plan year, patients should download the full drug formulary PDF from their insurer's website and search for "dulaglutide" or the brand name "Trulicity" to confirm tier and any required step therapy. Step therapy requirements are common: many Kentucky commercial plans require documented trial and failure of metformin and at least one other oral agent (often a sulfonylurea or SGLT-2 inhibitor) before approving a GLP-1 agonist.

The American Diabetes Association's 2024 Standards of Care in Diabetes states: "For patients with type 2 diabetes and established cardiovascular disease, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen independent of baseline HbA1c." [6] This guideline language supports prior authorization appeals when a Kentucky commercial insurer denies Trulicity for a patient with documented cardiovascular disease, because the denial contradicts major society guidance.

Patients denied coverage should request the plan's formulary exception process in writing, attach the prescriber's letter of medical necessity citing the ADA guideline above, and reference the REWIND trial data showing MACE reduction with dulaglutide. [2] Most commercial insurers in Kentucky must respond to urgent prior authorization requests within 72 hours under state prompt-pay laws.

How to Get the Lowest Possible Price on Trulicity in Kentucky

The cheapest path to Trulicity in Kentucky depends on insurance status, income, and clinical eligibility. There is no single answer, but the options rank roughly as follows by out-of-pocket cost.

For commercially insured patients with a co-pay above $25: the Lilly savings card typically reduces the cost to $25 per 28-day supply. This is almost always the least expensive option for this group.

For uninsured patients with income below $60,240 (single adult, 400% FPL in 2026): the Lilly Cares Foundation may provide Trulicity at no cost. Processing takes 2 to 4 weeks. The physician must complete and sign the enrollment form.

For uninsured patients above the Lilly Cares income cutoff: GoodRx or RxSaver coupons bring the retail Kentucky price to approximately $860, $910 per month at major chains. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) listed semaglutide but does not currently list brand-name dulaglutide at a reduced price. Mail-order pharmacy programs through Costco or Sam's Club sometimes offer slight discounts over retail.

For patients whose prescriber determines a compounded formulation is clinically appropriate: a licensed 503A pharmacy in Kentucky may prepare dulaglutide at $150, $350 per month. Patients must have a valid prescription and should confirm the pharmacy holds an active Kentucky Board of Pharmacy license.

The National Kidney Foundation notes that GLP-1 agents including dulaglutide show renoprotective signals in some datasets, which may support coverage arguments for patients with diabetic kidney disease. [7] Payers tend to respond more favorably to prior authorization requests that cite both cardiovascular and renal complication risk.

Clinical Dosing and Administration: What Kentucky Patients Need to Know

Trulicity is available in four doses: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg, all administered as once-weekly subcutaneous injections using a single-dose pen. The standard starting dose is 0.75 mg once weekly for 4 weeks, followed by escalation to 1.5 mg. Further increases to 3 mg and then 4.5 mg are made in 4-week increments based on tolerability and glycemic response. [1]

The injection can be given on any day of the week, with or without meals. If a dose is missed and the next scheduled dose is more than 3 days away, the missed dose may be administered. If the next scheduled dose is within 3 days, the missed dose should be skipped and the regular schedule resumed.

The most common adverse effects are gastrointestinal: nausea occurs in approximately 12 to 21% of patients across dose levels in key trials, vomiting in 6 to 13%, and diarrhea in 8 to 12%. [1] These effects are typically dose-dependent and diminish after the first 4 to 8 weeks. Kentucky patients beginning therapy should plan the first injection for a day that allows staying near home in case nausea is significant.

Contraindications include personal or family history of medullary thyroid carcinoma or MEN2. Dulaglutide is not approved for type 1 diabetes or diabetic ketoacidosis. Renal dose adjustment is not required, though clinical monitoring is recommended in patients with severe chronic kidney disease. [1]

Comparing Trulicity to Other GLP-1 Options Available in Kentucky

Kentucky patients who find Trulicity unaffordable or not covered by their plan have several alternative GLP-1 receptor agonists to discuss with their provider.

Semaglutide (Ozempic) at 0.5 mg, 1 mg, or 2 mg weekly is the most direct comparator. The SUSTAIN-6 trial (N=3,297) showed semaglutide reduced MACE by 26% compared with placebo over 104 weeks, a larger relative risk reduction than REWIND reported for dulaglutide, though direct head-to-head data are limited. [8] Ozempic's cash price in Kentucky is similarly in the $900, $980 per month range, and Novo Nordisk offers a comparable savings card program.

Exenatide extended-release (Bydureon BCise) is weekly and listed at a lower price point. Liraglutide (Victoza) is a daily injection with a strong cardiovascular evidence base from LEADER (N=9,340, HR 0.87 to 95% CI 0.78, 0.97 for MACE vs. placebo). [9] Neither exenatide ER nor liraglutide is dramatically cheaper at cash pay in 2026, but formulary placement varies enough that switching agents may reduce out-of-pocket cost for some insured Kentucky patients.

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 agonist with demonstrated superiority to semaglutide in HbA1c reduction in SURPASS-2 (N=1,879), reducing HbA1c by 2.01, 2.30 percentage points versus 1.86 for semaglutide 1 mg. [10] Lilly offers a savings card for Mounjaro as well. For Kentucky Medicaid patients, neither Trulicity nor Mounjaro is currently covered under standard formulary terms.

The prescribing decision among these agents should account for cardiovascular history, weight loss goals, injection frequency preference, and most practically, which product a patient's insurance will actually cover.